Akebia Therapeutics, Inc. (AKBA): Nasdaq/NYSE listing notice — Akebia gets 180-day extension to May 2023 to regain Nasdaq bid price compliance; transfer to Capital Market

Akebia Therapeutics, Inc.

Received 180-day extension from Nasdaq to regain $1.00 bid price compliance until May 8, 2023.
Failed to meet initial compliance deadline of November 8, 2022.
Transfer from Nasdaq Global Market to Nasdaq Capital Market approved, effective November 11, 2022.
Stock continues trading under symbol AKBA; if not compliant by May 8, 2023, delisting process may begin.
Company indicated intention to cure deficiency via reverse stock split if necessary.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Akebia Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na

View on SEC.gov

Browse all listing & compliance notices →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-282578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.